1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Roche

Roche

  • July 2020
  • 89 pages
  • ID: 5779840
  • Format: PDF
  • Pharma Intelligence

Summary

Table of Contents

PharmaVitae explores Roche’s prescription pharmaceutical performance and outlook over 2019–29.

Snapshot
Overview – Roche is poised to grow despite significant biosimilar headwinds to legacy franchises, with several new blockbusters and a strong late-stage pipeline.
Key themes – [1] Roche will see near-term growth even as key franchises encounter heavy biosimilar competition, as recent launches have been very strong [2] Ocrevus, Perjeta, Tecentriq, and Hemlibra are all seeing rapid growth at blockbuster levels [3] Roche’s recent string of acquisitions reflects the company’s ambition to reinforce its dominance in oncology, in anticipation of biosimilar erosion of its leading brands.

Model updates (24 July 2020)

Avastin forecast adjusted lower due to higher-than-expected biosimilar impact
Rituxan forecast adjusted lower due to higher-than-expected biosimilar impact
Actemra forecast adjusted higher due to COVID-19 benefits
Ocrevus forecast adjusted lower due to COVID-19 impacts to new patient starts in MS
Lucentis forecast adjusted lower due to COVID-19 impact on ophthalmology patient access
Pralsetinib forecast added due to in-licensing of asset from Blueprint Medicines
Satralizumab name changed to Enspryng due to approval in Japan.

Model updates (3 June 2020)

Avastin forecast adjusted lower due to biosimilar impact in the US
Rozlytrek forecast adjusted lower due to launch trend
Herceptin forecast adjusted lower due to biosimilar impact in the US
Ocrevus forecast adjusted higher due to strong demand trends and continued market share gains
Polivy forecast adjusted higher due to initial launch in Europe.

Model updates (4 March 2020)

Rituxan forecast adjusted higher due to lower-than-expected initial impact from biosimilar launches in the US
Herceptin forecast adjusted lower due to continued generic erosion and patients switching to Kadcyla
Perjeta forecast adjusted higher due to increased patient demand for adjuvant early breast cancer
Ocrevus forecast adjusted higher due to continued uptake across all types of multiple sclerosis and gains in earlier lines of therapy
Tecentriq forecast adjusted higher due to uptake in extensive-stage small cell lung cancer and triple-negative breast cancer, in addition to first-line non-small cell lung cancer
Kadcyla forecast adjusted higher due to adjuvant treatment and switching from Herceptin
Hemlibra forecast adjusted higher due to continued share gains in non-inhibitors and inhibitors
Alecensa forecast adjusted higher due to growth in first-line ALK+ non-small cell lung cancer and NDRL listing in China
Rozlytrek forecast adjusted lower due to slower-than-expected launch
Polivy forecast adjusted higher due to stronger-than-expected launch
Satralizumab forecast added
SPK-8011 forecast added
SRP-9001 forecast added after $1.15bn upfront licensing deal with Sarepta.

Model updates (17 October 2019)

Avastin forecast adjusted higher due to stronger sales in Rest of World, with notable growth in China driven by first-line CRC and NSCLC, along with longer duration of treatment
Perjeta forecast adjusted higher due to growth driven by early breast cancer (eBC) adjuvant setting
Tecentriq forecast adjusted higher due to growth in first-line NSCLC and launches in first-line SCLC and first-line TNBC
Kadcyla forecast adjusted higher due to stronger-than-expected initial uptake in the US after real-time oncology review approval in HER2-positive eBC
Hemlibra forecast adjusted higher due to strong uptake in the US and Japan in non-inhibitors.

Model updates (16 August 2019)

Avastin forecast adjusted higher due to lower-than-expected biosimilar impact in 2019
Ocrevus forecast adjusted higher due to continued strong adoption in the US
Tecentriq forecast adjusted higher due to rapid uptake in triple-negative breast cancer and extensive-stage small cell lung cancer
Kadcyla forecast adjusted higher due to initial uptake in the US after real-time oncology review approval in HER2-positive eBC
Hemlibra forecast adjusted higher due to strong uptake globally
Alecensa forecast adjusted lower due to less share gain in first-line NSCLC than anticipated
Rozlytrek (entrectinib) forecast added
Polivy (polatuzumab vedotin) forecast added
Idasanutlin forecast added
Ipatasertib forecast added
Faricimab forecast added
Satralizumab forecast added
Risdiplam forecast added.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Radiotherapy Devices Global Market Report 2020-30: Covid 19 Growth and Change

  • $ 4000
  • November 2020
  • 300 pages

Radiotherapy Devices Global Market Report 2020-30: Covid 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global radiotherapy ...

  • World
  • Ambulatory Care
  • Skin Cancer
  • Industry analysis

Global Lung Cancer Surgery Industry $ 5450 September 2020


ref:plp2020

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on